Bill Text: HI HB1032 | 2021 | Regular Session | Amended
Bill Title: Relating To The Uniform Controlled Substances Act.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Passed) 2021-07-07 - Act 233, 07/06/2021 (Gov. Msg. No. 1361). [HB1032 Detail]
Download: Hawaii-2021-HB1032-Amended.html
|
HOUSE OF REPRESENTATIVES |
H.B. NO. |
1032 |
|
THIRTY-FIRST LEGISLATURE, 2021 |
H.D. 1 |
|
|
STATE OF HAWAII |
|
|
|
|
|
|
|
|
||
|
|
||
A BILL FOR AN ACT
RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
SECTION
1. Section 329-14, Hawaii Revised
Statutes, is amended as follows:
1.
By amending subsection (b) to read:
"(b) Any of the following opiates, including their
isomers, esters, ethers, salts, and salts of isomers, esters, and ethers,
unless specifically excepted, whenever the existence of these isomers, esters,
ethers, and salts is possible within the specific chemical designation:
(1) Acetyl-alpha-methylfentanyl
(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
(2) Acetylmethadol;
(3) Allylprodine;
(4) Alphacetylmethadol (except
levo-alphacetylmethadol, levomethadyl acetate, or LAAM);
(5) Alphameprodine;
(6) Alphamethadol;
(7) Alpha-methylfentanyl
(N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide;
1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
(8) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(9) Benzethidine;
(10) Betacetylmethadol;
(11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);
(12) Beta-hydroxy-3-methylfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
(13) Betameprodine;
(14) Betamethadol;
(15) Betaprodine;
(16) Clonitazene;
(17) Dextromoramide;
(18) Diampromide;
(19) Diethylthiambutene;
(20) Difenoxin;
(21) Dimenoxadol;
(22) Dimepheptanol;
(23) Dimethylthiambutene;
(24) Dioxaphetyl butyrate;
(25) Dipipanone;
(26) Ethylmethylthiambutene;
(27) Etonitazene;
(28) Etoxeridine;
(29) Furethidine;
(30) Hydroxypethidine;
(31) Ketobemidone;
(32) Levomoramide;
(33) Levophenacylmorphan;
(34) 3-Methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
(35) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
(36) Morpheridine;
(37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
(38) Noracymethadol;
(39) Norlevorphanol;
(40) Normethadone;
(41) Norpipanone;
(42) Para-fluorofentanyl
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide;
(43) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;
(44) Phenadoxone;
(45) Phenampromide;
(46) Phenomorphan;
(47) Phenoperidine;
(48) Piritramide;
(49) Proheptazine;
(50) Properidine;
(51) Propiram;
(52) Racemoramide;
(53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
(54) Tilidine;
(55) Trimeperidine;
(56) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
(benzylfentanyl), its optical isomers, salts, and salts of isomers;
(57) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide
(thenylfentanyl), its optical isomers, salts, and salts of isomers;
(58) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,
(acetyl fentanyl), its optical, positional, and geometric isomers, salts, and
salts of isomers;
(59) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)
cyclohexylmethyl]benzamide), its isomers, esters, ethers, salts, and salts of
isomers, esters, and ethers;
(60) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its isomers,
esters, ethers, salts, and salts of isomers, esters, and ethers (Other names:
Butyryl fentanyl);
(61) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide, its isomers,
esters, ethers, salts, and salts of isomers, esters, and ethers (Other names:
beta-hydroxythiofentanyl);
(62) N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide,
its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other
names: Furanyl fentanyl);
(63) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide, its isomers,
esters, ethers, salts, and salts of isomers, esters, and ethers (Other names:
U-47700);
(64) 4-fluoroisobutyryl
fentanyl or para-fluoroisobutyryl [fenranyl] fentanyl [N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide];
(65) Acryl fentanyl or
acryloylfentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide]; [and]
(66) Ocfentanil [[N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiprtidin-4-yl)acetamide].]
[N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide];
(67) Cyclopropyl
fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide;
(68) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
(69) Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide)
(Other name: 2-fluorofentanyl); and
(70) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)."
2. By
amending subsection (e) to read:
"(e)
Depressants. Unless specifically
excepted, the schedule shall include any material, compound, mixture, or
preparation which contains any quantity of the substance:
(1) Mecloqualone;
[or]
(2) Methaqualone[.];
(3) Etizolam
(including its optical, positional, and geometric
isomers, salts, and salts of isomers, where possible); or
(4) Flualprazolam
(including its optical, positional, and geometric
isomers, salts, and salts of isomers, where possible)."
3. By
amending subsection (g) to read:
"(g) Any of the following cannabinoids, their
salts, isomers, and salts of isomers, unless specifically excepted, whenever
the existence of these salts, isomers, and salts of isomers is possible within
the specific chemical designation:
(1) Tetrahydrocannabinols;
meaning tetrahydrocannabinols naturally contained in a plant of the genus
Cannabis (cannabis plant), as well as synthetic equivalents of the substances
contained in the plant, or in the resinous extractives of Cannabis, sp. or
synthetic substances, derivatives, and their isomers with similar chemical structure
and pharmacological activity to those substances contained in the plant, such
as the following: Delta 1 cis or trans tetrahydrocannabinol, and their optical
isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers;
and Delta 3,4 cis or trans-tetrahydrocannabinol, and its optical isomers (since
nomenclature of these substances is not internationally standardized, compounds
of these structures, regardless of numerical designation of atomic positions,
are covered);
(2) Naphthoylindoles;
meaning any compound containing a 3-(1-naphthoyl)indole structure with
substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl,
alkenyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the naphthyl ring to any
extent;
(3) Naphthylmethylindoles;
meaning any compound containing a 1H-indol-3-yl-(1-naphthyl) methane structure
with substitution at the nitrogen atom of the indole ring by a alkyl,
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or
not further substituted in the indole ring to any extent and whether or not substituted
in the naphthyl ring to any extent;
(4) Naphthoylpyrroles;
meaning any compound containing a 3-(1-naphthoyl)pyrrole structure with
substitution at the nitrogen atom of the pyrrole ring by a alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
2-(4-morpholinyl) ethyl group whether or not further substituted in the pyrrole
ring to any extent, whether or not substituted in the naphthyl ring to any
extent;
(5) Naphthylmethylindenes;
meaning any compound containing a naphthylideneindene structure with
substitution at the 3-position of the indene ring by a alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl
or 2-(4-morpholinyl) ethyl group whether or not further substituted in the
indene ring to any extent, whether or not substituted in the naphthyl ring to
any extent;
(6) Phenylacetylindoles;
meaning any compound containing a 3-phenylacetylindole structure with
substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl
or 2-(4-morpholinyl) ethyl group whether or not further substituted in the
indole ring to any extent, whether or not substituted in the phenyl ring to any
extent;
(7) Cyclohexylphenols;
meaning any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with
substitution at the 5-position of the phenolic ring by a alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl
or 2-(4-morpholinyl) ethyl group whether or not substituted in the cyclohexyl
ring to any extent;
(8) Benzoylindoles;
meaning any compound containing a 3-(benzoyl) indole structure with
substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or
2-(4-morpholinyl) ethyl group whether or not further substituted in the indole
ring to any extent and whether or not substituted in the phenyl ring to any extent;
(9) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-naphthalenylmethanone (another trade
name is WIN 55,212-2);
(10) (6a,10a)-9-(hydroxymethyl)-6,
6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
(Other trade names are: HU-210/HU-211);
(11) Tetramethylcyclopropanoylindoles;
meaning any compound containing a 3-tetramethylcyclopropanoylindole structure
with substitution at the nitrogen atom of the indole ring by an alkyl,
haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
tetrahydropyranylmethyl group, whether or not further substituted in the indole
ring to any extent and whether or not substituted in the tetramethylcyclopropyl
ring to any extent;
(12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: APINACA, AKB48);
(13) Quinolin-8-yl
1-pentyl-1H-indole-3-carboxylate, its optical, positional, and geometric
isomers, salts, and salts of isomers (Other names: PB-22; QUPIC);
(14) Quinolin-8-yl
1-(5fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and
geometric isomers, salts, and salts of isomers (Other names: 5-fluoro-PB-22;
5F-PB-22);
(15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide,
its optical, positional, and geometric isomers, salts, and salts of isomers (Other
names: AB-FUBINACA);
(16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: ADB-PINACA);
(17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide,
its optical, positional, and geometric isomers, salts, and salts of isomers
(Other names: AB-CHMINACA);
(18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide,
and geometric isomers, salts, and salts of isomers (Other names: AB-PINACA);
(19) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone,
and geometric isomers, salts, and salts of isomers (Other names: THJ-2201);
(20) Methyl
[(1-(4-fluorobenzyl)-1 H-indazole-3-carbonyl)-L-valinate,] (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate,
and geometric isomers, salts, and salts of isomers (Other names: FUB-AMB[);],
Methyl
2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate,
MMB-FUBINACA, AMB-FUBINACA);
(21) (S)-methyl
2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, and
geometric isomers, salts, and salts of isomers (Other names: 5-fluoro-AMB, 5-fluoro-AMP);
(22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide,
and geometric isomers, salts, and salts of isomers (Other names: AKB48
N-(5-fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl analog, 5F-APINACA);
(23) N-adamantyl-1-fluoropentylindole-3-Carboxamide,
and geometric isomers, salts, and salts of isomers (Other names: STS-135, 5F-APICA;
5-fluoro-APICA);
(24) Naphthalen-1-yl
1-(5-fluoropentyl)-1H-indole-3-carboxylate, and geometric isomers, salts, and
salts of isomers (Other names: NM2201);
(25) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide,
and geometric isomers, salts, and salts of isomers (Other names: MAB-CHMINACA
and ADB-CHMINACA);
(26) Methyl
2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (Other
names: 5F-ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical, positional, and
geometric isomers, salts, and salts of isomers; and
SECTION
2. Section 329-16, Hawaii Revised
Statutes, is amended by amending subsection (f) to read as follows:
"(f) Immediate precursor. Unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances:
(1) Immediate precursor to amphetamine and
methamphetamine:
(A) Phenylacetone,
phenyl-2-propanone(P2P), benzyl methyl ketone, methyl benzyl ketone;
(2) Immediate precursors to phencyclidine (PCP):
(A) 1-phenylcyclohexylamine;
[and] or
(B) 1-piperidinocyclohexanecarbonitrile(PCC);
or
(3) Immediate precursor to Fentanyl:
(A) 4‑anilino-N-phenethyl-4-piperidine
(ANPP)[.]; or
(B) N-phenyl-N-(piperidin-4-yl)propionamide
(norfentanyl)."
SECTION
3. Section 329-20, Hawaii Revised
Statutes, is amended as follows:
1.
By amending subsection (b) to read:
"(b) Depressants. Any material, compound, mixture, or
preparation which contains any quantity of the following substances, including
its salts, isomers, esters, ethers, and salts of isomers, whenever the
existence of these isomers, esters, ethers, and salts is possible within the
specific chemical designation, that has a degree of
danger or probable danger associated with a depressant effect on the central
nervous system:
(1) Alprazolam;
(2) Barbital;
(3) Bromazepam;
(4) Butorphanol;
(5) Camazepam;
(6) Carisoprodol;
(7) Chloral betaine;
(8) Chloral hydrate;
(9) Chlordiazepoxide;
(10) Clobazam;
(11) Clonazepam;
(12) Clorazepate;
(13) Clotiazepam;
(14) Cloxazolam;
(15) Delorazepam;
(16) Dichloralphenazone (Midrin);
(17) Diazepam;
(18) Estazolam;
(19) Ethchlorvynol;
(20) Ethinamate;
(21) Ethyl loflazepate;
(22) Fludiazepam;
(23) Flunitrazepam;
(24) Flurazepam;
(25) Fospropofol (Lusedra);
(26) Halazepam;
(27) Haloxazolam;
(28) Ketazolam;
(29) Loprazolam;
(30) Lorazepam;
(31) Lormetazepam;
(32) Mebutamate;
(33) Medazepam;
(34) Meprobamate;
(35) Methohexital;
(36) Methylphenobarbital (mephorbarbital);
(37) Midazolam;
(38) Nimetazepam;
(39) Nitrazepam;
(40) Nordiazepam;
(41) Oxazepam;
(42) Oxazolam;
(43) Paraldehyde;
(44) Petrichloral;
(45) Phenobarbital;
(46) Pinazepam;
(47) Prazepam;
(48) Quazepam;
(49) Suvorexant;
(50) Temazepam;
(51) Tetrazepam;
(52) Triazolam;
(53) Zaleplon;
(54) Zolpidem; [and]
(55) Zopiclone (Lunesta)[.]; and
(56) Brexanolone."
2. By
amending subsection (d) to read:
"(d) Stimulants. Unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following substances
having a stimulant effect on the central nervous system, including its salts,
isomers, and salts of such isomers whenever the existence of such salts, isomers,
and salts of isomers is possible within the specific chemical designation:
(1) Cathine ((+)-norpseudoephedrine);
(2) Diethylpropion;
(3) Fencamfamin;
(4) Fenproporex;
(5) Mazindol;
(6) Mefenorex;
(7) Modafinil;
(8) Phentermine;
(9) Pemoline (including organometallic complexes
and chelates thereof);
(10) Pipradrol;
(11) Sibutramine;
(12) SPA (1-dimethylamino-1,2-diphenylethane,
lefetamine); [and]
(13) Lorcaserin[.]; and
(14) Solriamfetol."
SECTION
4. Section 329-22, Hawaii Revised
Statutes, is amended to read as follows:
"§329-22
Schedule V. (a) The controlled substances listed in this
section are included in schedule V.
(b) Narcotic drugs containing nonnarcotic active
medicinal ingredients. Any compound,
mixture, or preparation containing limited quantities of any of the following
narcotic drugs, which also contains one or more nonnarcotic active medicinal
ingredients in sufficient proportion to confer upon the compound, mixture, or
preparation, valuable medicinal qualities other than those possessed by the
narcotic drug alone:
(1) Not more than 200 milligrams of codeine, or
any of its salts, per 100 milliliters or per 100 grams;
(2) Not more than 100 milligrams of dihydrocodeine,
or any of its salts, per 100 milliliters or per 100 grams;
(3) Not more than 100 milligrams of ethylmorphine,
or any of its salts, per 100 milliliters or per 100 grams;
(4) Not more than 2.5 milligrams of diphenoxylate
and not less than 25 micrograms of atropine sulfate per dosage unit;
(5) Not more than 100 milligrams of opium per 100
milliliters or per 100 grams; and
(6) Not more than 0.5 milligram of difenoxin and
not less than 25 micrograms of atropine sulfate per dosage unit.
(c) Stimulants.
Unless specifically exempted or excluded or unless listed in another
schedule, any material, compound, mixture, or preparation that contains any
quantity of the following substances having a stimulant effect on the central
nervous system, including its salts, isomers, and salts of isomers.
(d) Depressants. Unless specifically exempted or excluded or
unless listed in another schedule, any material, compound, mixture, or
preparation that contains any quantity of the following substances having a
depressant effect on the central nervous system, including its salts, isomers,
and salts of isomers:
(1) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide],
(Vimpat);
(2) Pregabalin
[(S)-3-(aminomethyl)-5-methylhexanoic acid]; and
(3) Brivaracetam ((2S)-2[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide)
(Other names: BRV; UCB-34714; Briviact) and its salts.
[(e) Approved cannabidiol drugs. A drug product in finished dosage formulation
that has been approved by the United States Food and Drug Administration that
contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol)
derived from cannabis and no more than 0.1 percent (w/w) residual
tetrahydrocannabinols.]"
SECTION
5. Statutory material to be repealed is bracketed
and stricken. New statutory material is
underscored.
SECTION
6. This Act shall take effect upon its
approval.
Report Title:
Uniform Controlled Substances Act
Description:
Updates the Uniform Controlled Substances Act, chapter 329, Hawaii Revised Statutes, to make it consistent with amendments in the federal controlled substances law as required by section 329-11, Hawaii Revised Statutes. (HD1)
The summary description
of legislation appearing on this page is for informational purposes only and is
not legislation or evidence of legislative intent.
